NHF Noble Hlth FD.

    Noble Health Fund VCT

Changes at Noble Health Fund VCT

Noble  Health Fund VCT (`Noble Health') announced the appointment of a new  non-
executive  director, Peter Arthur on 22 April 2008.  Peter brings  a  wealth  of
experience  in  fund  management having been Managing  Director  of  ISIS  Asset
Management (now F&C Investments) and Edinburgh Fund Managers.

Following the decision of the current chairman, Gill Nott, to step down from her
role and resign from the Board at the AGM on 5 June, Noble Health announces that
one  of  the current non-executive directors, Charles Pinney, will take over  as
Chairman.

Noble  Health's fund manager, Noble Fund Managers, jointly announces changes  to
its  investment management team.  Gerard Tardy, who was one of the  founders  of
the  healthcare  investment  team along with Louis  Nisbet,  is  retiring.   The
healthcare  team was strengthened in 2007 with the arrival of two  new  managers
with  significant life science investment experience, Paul Toon, who  joined  as
Head of Unquoted Investments at Noble Fund Managers and who leads the healthcare
team, and Dr Stephane Mery, who joined as Investment Director.

The  Board  and  Noble  believe the recent appointments enhance  Noble  Health's
position as one of the leading healthcare investment teams in the UK.


30 April 2008


Notes:

Peter  Arthur  was  Managing Director of the institutional and investment  trust
businesses  at  Isis Asset Management (now F&C Investments) from 1999  to  2004.
Prior  to  that he was legal counsel to Franklin Templeton Global Investors  and
joint managing director of Edinburgh Fund Managers where he worked for 14 years.
Peter  also chairs Artemis AiM VCT 2 plc and Aberdeen Asian Income Fund Ltd  and
is  a director of a number of private companies. He is a qualified solicitor and
chartered secretary.

Charles Pinney is currently a non-executive director of Noble Aim VCT plc and  a
consultant  to Rathbones Investment Management. Mr Pinney was, from  1994  until
2003,  a  director of Barclays Private Bank Limited with overall  responsibility
for  the  operations of the investment department. He was a director  of  APCIMS
(the  Association  of Private Client Investment Managers and Stockbrokers)  from
1998 to 2003. After graduating from Cambridge University, he joined Dunlops  and
qualified as a Certified and Corporate Accountant. He joined Lazard Brothers  in
1972 and worked in both the private client and corporate finance departments. In
1980 he moved to the private client department of de Zoete & Bevan and became  a
partner  in  1984.  After its takeover by Barclays, he was  a  director  of  BZW
Portfolio Management Limited and subsequently Barclays Private Bank Limited.  Mr
Pinney is also a Fellow of the Securities Institute.

Paul  Toon began his career at Merrill Lynch in its European M&A Group.  He  has
15  years experience in investing in, managing and advising technology and  life
science  companies.  In 2004 Paul led the acquisition of,  and  became  Managing
Partner of, Innoven Partenaires, one of France's leading venture capital  firms,
establishing  it as the leading national manager of FCPIs (VCT  type  funds)  by
performance  within just two years. During this time Paul oversaw  several  IPOs
and  trade  sales  of  portfolio companies in the  life  sciences  sector.  Paul
graduated from Oxford University.

Dr  Stephane  Mery was in the Worldwide Business Development team at  SmithKline
Beecham   gaining   expertise   in  licensing  and   acquisitions   within   the
pharmaceutical sector. Stephane is also the manager of Bloomsbury Bioseed  Fund,
a  leading  London-based healthcare seed fund, which he has managed since  2000.
Stephane  has  an  MBA from INSEAD and qualified from the Veterinary  School  of
Alfort (Paris).

Louis  Nisbet  was awarded a PhD in biochemistry from Imperial College,  London,
and   subsequently   held   senior  management  positions   within   the   major
pharmaceutical companies Hoffmann-La Roche, Glaxo Group and SmithKline  Beecham.
He  has  founded, built and realised gains in several health and  life  sciences
companies  and  is  a  Board  Director of five of  the  Noble  Health  Fund  VCT
companies.  He was a founding Director of Sitka in 1999 and of the Sitka  Health
Fund  VCT  (the  former  name  for  Noble Health  Fund  VCT)  in  2001  and  was
instrumental in raising funds under management. Sitka was acquired by Noble Fund
Managers in October 2005.

Noble Hlth FD. (LSE:NHF)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025

Noble Hlth FD. (LSE:NHF)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025